SCHEMBL6428632

SCHEMBL6428632

COc1cc2c(cc1OC)CN(C(=O)CC1SC(NC3CCCCC3)=NC1=O)CC2

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.51
RAB9A P51151 1/20 0.51
ALDH1A1 P00352 4/20 0.49
KDM4E B2RXH2 3/20 0.49
LMNA P02545 1/20 0.49
TP53 P04637 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
HSD17B10 Q99714 1/20 0.49
KMT2A Q03164 2/20 0.48
MEN1 O00255 1/20 0.48
DPP4 P27487 2/20 0.45
DPP8 Q6V1X1 2/20 0.45
NPC1 O15118 1/20 0.45
PDE4B Q07343 4/20 0.44
PDE4D Q08499 1/20 0.44
POLB P06746 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MAPK1 P28482 1/20 0.42
DPP7 Q9UHL4 1/20 0.42
ABCB1 P08183 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6427188 0.84 ALDH1A1 (0.57) SMN1; SMN2ALDH1A1KDM4ELMNANPSR1
SCHEMBL6426510 0.84 ALDH1A1 (0.57) SMN1; SMN2ALDH1A1KDM4ELMNANPSR1
SCHEMBL6393517 0.83 ALDH1A1 (0.55) SMN1; SMN2RAB9AALDH1A1KDM4ELMNA
SCHEMBL6428776 0.79 ALDH1A1 (0.49) RAB9AALDH1A1KDM4ELMNANPSR1
SCHEMBL6507694 0.78 ALDH1A1 (0.46) SMN1; SMN2ALDH1A1KDM4ELMNANPSR1
SCHEMBL6502742 0.78 TSHR (0.49) SMN1; SMN2RAB9AALDH1A1KDM4EHSD17B10
SCHEMBL6425891 0.78 TSHR (0.49) SMN1; SMN2RAB9AALDH1A1KDM4EHSD17B10
SCHEMBL6501368 0.78 TSHR (0.49) SMN1; SMN2RAB9AALDH1A1KDM4EHSD17B10
SCHEMBL6429260 0.78 TSHR (0.49) SMN1; SMN2RAB9AALDH1A1KDM4EHSD17B10
SCHEMBL6427136 0.78 TSHR (0.49) SMN1; SMN2RAB9AALDH1A1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050239853-A1 New compounds BIOVITRUM AB (SE) 2005-10-27 US claimed
WO-2005075471-A2 THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS BIOVITRUM AB (SE) 2005-08-18 WO claimed
US-20050239853-A1 New compounds BIOVITRUM AB (SE) 2005-10-27 US disclosed
WO-2005075471-A2 THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS BIOVITRUM AB (SE) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239853-A1 New compounds HSD11B1, CYP11B1, HSD3B1 SMN1; SMN2 3733/4885RAB9A 2649/4885ALDH1A1 67/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.